ARGX · Argenx SE
$851.29
-5.65 (-0.66%)
At close · Aug 14
Market Cap
$52.69B
Shares
62.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$851.29
Open$845.36
Day$837.42–852.08
52W close$652.43–939.68
Avg vol 30d287K
Short int1.3M · 2.1% float · 4.7d
Short vol57%
Last earningsDec 31, 2025
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−3%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
69%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+3%
trailing
YTD return
+1%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $880 › 200d $832 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +82 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.15% of float · ▼ -13.3% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
499 holders — near 3-yr high, broad support
Squeeze score
44
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
31%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
3.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2024
Combined SG&A and R&D spend
· 2024
$2B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
69%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $880 › 200d $832 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +82 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.15% of float · ▼ -13.3% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
499 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $652
Now $851 · 69%
Range high $940
vs 200-day avg +2%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARGX
this stock
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
|
ONC
BeOne Medicines Ltd.
|
$530.72B | +14.4% | +22179.2% | 816.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.16B | +4.1% | +20.8% | 19.8 | 3.3% |
|
CSLLY
Csl Ltd
|
$46.19B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARGX | -1.6% | -1.1% | +3.0% | -0.3% | +1.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.0% | -5.5% | -10.7% | -4.2% | -12.6% |